US 6277375B1
· Ward
· 2001
[cited by applicant]
US 8088376B2
· Chamberlain et al.
· 2012
[cited by applicant]
US 9334331B2
· Igawa et al.
· 2016
[cited by applicant]
US 20140056879A1
· Lazar
· 2014
[cited by applicant]
US 20240123020A1
· Illingworth et al.
· 2024
[cited by applicant]
EP 2153847A1
· 2010
[cited by applicant]
WO WO9734631A1
· 1997
[cited by applicant]
WO WO9823289A1
· 1998
[cited by applicant]
WO WO2004029207A2
· 2004
[cited by applicant]
WO WO2004099249A2
· 2004
[cited by applicant]
WO WO2006019447A1
· 2006
[cited by applicant]
WO WO2006053301A2
· 2006
[cited by applicant]
WO WO2009086320A1
· 2009
[cited by applicant]
WO WO2018035107A2
· 2018
[cited by applicant]
WO WO2023031615A1
· 2023
[cited by applicant]
Booth et al., “Extending human IgG half-life using structure-guided design.”
[cited by applicant]
Borrok et al., “An “Fc-silenced” IgG1 format with extended half-life designed for improved stability.”
[cited by applicant]
Castelino et al., “Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma.”
[cited by applicant]
Chrencik et al., “Crystal structure of antagonist bound human lysophosphatidic acid receptor 1.”
[cited by applicant]
Dall'Acqua et al., “Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences.”
[cited by applicant]
Dall'Acqua et al., “Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).” Journal of Biological Chemistry 281.33 (2006): 23514-23524.
[cited by applicant]
Datta-Mannan et al., “FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys.”
[cited by applicant]
Datta-Mannan et al., “Monoclonal antibody clearance: impact of modulating the interaction of IgG with the neonatal Fc receptor.”
[cited by applicant]
Datta-Mannan et al., “Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates.”
[cited by applicant]
Forbes et al., “Combining liver-and blood-stage malaria viral-vectored vaccines: investigating mechanisms of CD8+ T cell interference.”
[cited by applicant]
Hinton et al., “An engineered human IgG1 antibody with longer serum half-life.”
[cited by applicant]
Hinton et al., “Engineered human IgG antibodies with longer serum half-lives in primates.”
[cited by applicant]
Hollevoet et al., “State of play and clinical prospects of antibody gene transfer.”
[cited by applicant]
Igawa et al., “Engineered monoclonal antibody with novel antigen-sweeping activity in vivo.”
[cited by applicant]
Kabat, Sequences of proteins of
[cited by applicant]
Ko et al., “Recent achievements and challenges in prolonging the serum half-lives of therapeutic IgG antibodies through Fc engineering.”
[cited by applicant]
Lee et al., “An engineered human Fc domain that behaves like a pH-toggle switch for ultra-long circulation persistence.”
[cited by applicant]
Lee et al., “Lysophosphatidic acid receptor 1 inhibitor, AM095, attenuates diabetic nephropathy in mice by downregulation of TLR4/NF-
[cited by applicant]
Li et al., “Blocking lysophosphatidic acid receptor 1 signaling inhibits diabetic nephropathy in db/db mice.”
[cited by applicant]
Liu et al., “Fc-engineering for modulated effector functions-improving antibodies for cancer treatment.”
[cited by applicant]
Mackness et al., “Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life.”
[cited by applicant]
Miyabe et al., “Abrogation of lysophosphatidic acid receptor 1 ameliorates murine vasculitis.”
[cited by applicant]
Nishikawa et al., “Therapeutic efficacy of a novel LPA1 receptor antagonist, UD-009, in a bleomycin-induced pulmonary fibrosis model.” European Respiratory Journal 48 (2016): PA4032.
[cited by applicant]
Orosa et al., “Lysophosphatidic acid receptor inhibition as a new multipronged treatment for rheumatoid arthritis.”
[cited by applicant]
Palmer et al., “Randomized, double-blind, placebo-controlled, phase 2 trial of BMS-986020, a lysophosphatidic acid receptor antagonist for the treatment of idiopathic pulmonary fibrosis.”
[cited by applicant]
Petkova et al., “Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.”
[cited by applicant]
Pradere et al., “LPA1 receptor activation promotes renal interstitial fibrosis.”
[cited by applicant]
Rancoule et al., “Lysophosphatidic acid impairs glucose homeostasis and inhibits insulin secretion in high-fat diet obese mice.”
[cited by applicant]
Robbie et al., “A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults.”
[cited by applicant]
Sakai et al., “LPAR1-induced cytoskeleton reorganization drives fibrosis through CTGF-dependent fibroblast proliferation.” FASEB J. 27.5 (2013):1830-1846.
[cited by applicant]
Sasagawa et al., “The significance of plasma lysophospholipids in patients with renal failure on hemodialysis.”
[cited by applicant]
Saunders, “Conceptual approaches to modulating antibody effector functions and circulation half-life.”
[cited by applicant]
Shields et al., “High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR.”
[cited by applicant]
Swaney et al., “A novel, orally active LPA1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin model.”
[cited by applicant]
Swaney et al., “Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist.”
[cited by applicant]
Tager et al., “The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak.”
[cited by applicant]
Tokumura et al., “Elevated serum levels of arachidonoyl-lysophosphatidic acid and sphingosine 1-phosphate in systemic sclerosis.”
[cited by applicant]
Vaccaro et al., “Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies.”
[cited by applicant]
Vaccaro et al., “Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels.”
[cited by applicant]
Watanabe et al., “Plasma lysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severity.”
[cited by applicant]
Zalevsky et al., “Enhanced antibody half-life improves in vivo activity.”
[cited by applicant]
Zhang et al., “Lysophosphatidic acid receptor antagonism protects against diabetic nephropathy in a type 2 diabetic model.”
[cited by applicant]
Al Qaraghuli et al., “Antibody-protein binding and conformational changes: identifying allosteric signalling pathways to engineer a better effector response”, Scientific reports 10.1: 13696 (2020).
[cited by applicant]
Casset et al., “A peptide mimetic of an anti-CD4 monoclonal antibody by rational design,” Biochem Biophys Res Comm, 307:198-205 (2003).
[cited by applicant]
Chen et al., “Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen”, Journal of molecular biology 293.4: 865-881 (1999).
[cited by applicant]
Edwards et al., “The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS”, Journal of molecular biology 334.1: 103-118 (2003).
[cited by applicant]
Goel et al., “Plasticity within the antigen-combining site may manifest as molecular mimicry in the humoral immune response”, The Journal of Immunology 173.12: 7358-7367 (2004).
[cited by applicant]
Holm et al., “Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1”, Molecular Immunology 44.6: 1075-1084 (2007).
[cited by applicant]
Khan et al., “Adjustable locks and flexible keys: plasticity of epitope-paratope interactions in germline antibodies”, The Journal of Immunology 192.11: 5398-5405 (2014).
[cited by applicant]
Lloyd et al., “Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens,” Protein Engineering, Design & Selection, 22(3): 159-168 (2…
[cited by applicant]
Maccallum et al., “Antibody-antigen interactions: contact analysis and binding site topography”, Journal of molecular biology 262.5: 732-745 (1996).
[cited by applicant]
Paul, “Fundamental Immunology”, 3rd Edition, Raven Press, NY, pp. 292-295 (1993).
[cited by applicant]
Poosarla et al., “Computational De Novo Design of Antibodies Binding to a Peptide With High Affinity,” Biotechnology and Bioengineering, 114(6): 1331-1342 (2017).
[cited by applicant]
Rabia et al., “Understanding and overcoming trade-offs between antibody affinity, specificity, stability and solubility”, Biochemical Engineering Journal 137: 365-374 (2018).
[cited by applicant]
Vajdos et al., “Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis”, Journal of molecular biology 320.2: 415-428 (2002).
[cited by applicant]
Carmona-Rosas et al., “A549 cells as a model to study endogenous LPA1receptor signaling and regulation,” European Journal of Pharmacology 815 (2017): 258-265.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/GB22/52240 dated Dec. 16, 2022.
[cited by applicant]
Jung, “Isolation of Single Chain Antibodies Specific to Lysophosphatidic Acid Receptor 1 (LPA1) from a M13 Phage Display Library Using Purified LPA1 Stabilized in Nanodiscs,” Bulletin of the Korean Chemical Society 40.7…
[cited by applicant]
Binz et al., “Designing repeat proteins: well-expressed, soluble, and stable proteins from combinatorial libraries of consensus snkyrin repeat proteins,” Journal of Molecular Biology 332.2 (2003): 489-503.
[cited by applicant]